表紙
市場調査レポート

Alder Biopharmaceuticals Inc.の製品パイプライン分析

Alder Biopharmaceuticals Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 276019
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。
Back to Top
Alder Biopharmaceuticals Inc.の製品パイプライン分析 Alder Biopharmaceuticals Inc. - Product Pipeline Review - 2015
出版日: 2015年10月30日 ページ情報: 英文 32 Pages
概要

Alder Biopharmaceuticals Inc.は米国に本社をおくバイオテクノロジー企業で、抗体治療薬の開発、生産、販売を行っています。対象疾患は癌、免疫疾患、炎症疾患です。

当レポートでは、Alder Biopharmaceuticals Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Alder Biopharmaceuticals Inc. の基本情報

  • Alder Biopharmaceuticals Inc. の概要
  • 主要情報
  • 企業情報

Alder Biopharmaceuticals Inc. :R&Dの概要

  • 主な治療範囲

Alder Biopharmaceuticals Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Alder Biopharmaceuticals Inc. :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Alder Biopharmaceuticals Inc.:薬剤プロファイル

  • ALD-403
  • clazakizumab
  • ALD-806
  • ALD-901
  • Monoclonal Antibody-1 for Undisclosed Indication
  • Monoclonal Antibody-2 for Undisclosed Indication
  • Monoclonal Antibody-3 for Undisclosed Indication
  • Monoclonal Antibody-4 for Undisclosed Indication

Alder Biopharmaceuticals Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Alder Biopharmaceuticals Inc. :最新のパイプライン情報

Alder Biopharmaceuticals Inc. :現在休止中のプロジェクト

Alder Biopharmaceuticals Inc. :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07729CDB

Summary

Global Markets Direct's, 'Alder Biopharmaceuticals Inc. - Product Pipeline Review - 2015', provides an overview of the Alder Biopharmaceuticals Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alder Biopharmaceuticals Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alder Biopharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alder Biopharmaceuticals Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alder Biopharmaceuticals Inc.'s pipeline products

Reasons to buy

  • Evaluate Alder Biopharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alder Biopharmaceuticals Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alder Biopharmaceuticals Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alder Biopharmaceuticals Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alder Biopharmaceuticals Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alder Biopharmaceuticals Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alder Biopharmaceuticals Inc. Snapshot
    • Alder Biopharmaceuticals Inc. Overview
    • Key Information
    • Key Facts
  • Alder Biopharmaceuticals Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alder Biopharmaceuticals Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alder Biopharmaceuticals Inc. - Pipeline Products Glance
    • Alder Biopharmaceuticals Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Alder Biopharmaceuticals Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Alder Biopharmaceuticals Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Alder Biopharmaceuticals Inc. - Drug Profiles
    • ALD-403
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clazakizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALD-1613
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody-2 for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody-3 for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody-4 for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alder Biopharmaceuticals Inc. - Pipeline Analysis
    • Alder Biopharmaceuticals Inc. - Pipeline Products by Target
    • Alder Biopharmaceuticals Inc. - Pipeline Products by Route of Administration
    • Alder Biopharmaceuticals Inc. - Pipeline Products by Molecule Type
    • Alder Biopharmaceuticals Inc. - Pipeline Products by Mechanism of Action
  • Alder Biopharmaceuticals Inc. - Recent Pipeline Updates
  • Alder Biopharmaceuticals Inc. - Dormant Projects
  • Alder Biopharmaceuticals Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alder Biopharmaceuticals Inc., Key Information
  • Alder Biopharmaceuticals Inc., Key Facts
  • Alder Biopharmaceuticals Inc. - Pipeline by Indication, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Stage of Development, 2015
  • Alder Biopharmaceuticals Inc. - Monotherapy Products in Pipeline, 2015
  • Alder Biopharmaceuticals Inc. - Phase III, 2015
  • Alder Biopharmaceuticals Inc. - Phase II, 2015
  • Alder Biopharmaceuticals Inc. - Preclinical, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Target, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Route of Administration, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Molecule Type, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2015
  • Alder Biopharmaceuticals Inc. - Recent Pipeline Updates, 2015
  • Alder Biopharmaceuticals Inc. - Dormant Developmental Projects,2015

List of Figures

  • Alder Biopharmaceuticals Inc. - Pipeline by Top 10 Indication, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Stage of Development, 2015
  • Alder Biopharmaceuticals Inc. - Monotherapy Products in Pipeline, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Top 10 Target, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top